Intake of Energy Drinks Before and During Pregnancy and Adverse Pregnancy Outcomes.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Nov 2023
Historique:
medline: 21 11 2023
pubmed: 20 11 2023
entrez: 20 11 2023
Statut: epublish

Résumé

Consumption of energy drinks has increased drastically in recent years, particularly among young people. It is unknown whether intake of energy drinks is associated with health during pregnancy. To examine associations of energy drink intake before and during pregnancy with risk of adverse pregnancy outcomes (APOs). This prospective cohort study included data from women enrolled in the Nurses' Health Study 3 (NHS3) between June 1, 2010, and September 27, 2021, and the Growing Up Today Study (GUTS) who reported 1 or more singleton pregnancy from January 1, 2011, to June 1, 2019. Data were analyzed from October 1, 2021, to September 28, 2023. Intake of energy drinks, assessed by food frequency questionnaire. The main outcomes were self-reported APOs, including pregnancy loss, gestational diabetes, gestational hypertension, preeclampsia, or preterm birth, and a composite APO, defined as development of any of the APOs. Risk of APOs was compared between consumers and nonconsumers of energy drinks. This study included 7304 pregnancies in 4736 participants with information on prepregnancy energy drink intake and 4559 pregnancies in 4559 participants with information on energy drink intake during pregnancy. There were 1691 GUTS participants (mean [SD] age, 25.7 [2.9] years) and 3045 NHS3 participants (mean [SD] age, 30.2 [4.1] years). At baseline, 230 GUTS participants (14%) and 283 NHS3 participants (9%) reported any intake of energy drinks. While no associations were found for pregnancy loss (odds ratio [OR], 0.89; 95% CI, 0.71-1.11), preterm birth (OR, 1.07; 95% CI, 0.71-1.61), gestational diabetes (OR, 0.89; 95% CI, 0.58-1.35), preeclampsia (OR, 0.73; 95% CI, 0.41-1.30), or the composite APO (OR, 1.05; 95% CI, 0.87-1.26), prepregnancy energy drink use was associated with a higher risk of gestational hypertension (OR, 1.60; 95% CI, 1.12-2.29). A significant interaction was found between age and energy drink intake in relation to hypertensive disorders (P = .02 for interaction for gestational hypertension; P = .04 for interaction for any hypertensive disorders), with stronger associations for participants above the median age. No associations of energy drink intake during pregnancy with any of the APOs were found in NHS3 (eg, any APO: OR, 0.86; 95% CI, 0.41-1.79). In this study, energy drink intake before pregnancy was associated with an elevated risk of gestational hypertension. Given the low prevalence of energy drink intake and low consumption levels among users, the results should be interpreted cautiously.

Identifiants

pubmed: 37983030
pii: 2812078
doi: 10.1001/jamanetworkopen.2023.44023
pmc: PMC10660164
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2344023

Références

Am J Epidemiol. 1984 Nov;120(5):727-33
pubmed: 6541871
J Caffeine Res. 2016 Jun 1;6(2):49-63
pubmed: 27274415
Public Health Nutr. 2023 Jul;26(7):1424-1435
pubmed: 36214079
Sports Health. 2021 May-Jun;13(3):265-277
pubmed: 33211984
Front Public Health. 2017 Aug 31;5:225
pubmed: 28913331
Am J Epidemiol. 2018 May 1;187(5):1051-1063
pubmed: 29036411
Paediatr Child Health. 2017 Oct;22(7):406-410
pubmed: 29491725
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Ann Intern Med. 2018 Aug 21;169(4):224-232
pubmed: 29971437
Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36
pubmed: 1632423
Ann Pharmacother. 2016 Oct;50(10):808-15
pubmed: 27340146
Am J Prev Med. 2019 Jun;56(6):827-833
pubmed: 31005465
Am J Epidemiol. 2017 Apr 1;185(7):570-584
pubmed: 28338828
J Med Case Rep. 2020 Jan 29;14(1):23
pubmed: 31992329
Public Health Nutr. 2019 Oct;22(14):2531-2542
pubmed: 31317857
Food Chem Toxicol. 2019 Aug;130:109-121
pubmed: 31112702
Nutr J. 2007 Oct 31;6:35
pubmed: 17974021
Am J Clin Nutr. 2020 Dec 10;112(6):1429-1437
pubmed: 32778894
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Int J Public Health. 2016 Apr;61(3):299-306
pubmed: 26888471
Int J Epidemiol. 1989 Dec;18(4):858-67
pubmed: 2621022
Am J Epidemiol. 1997 Jan 1;145(1):58-67
pubmed: 8982023
Am J Public Health. 2016 Sep;106(9):1573-81
pubmed: 27459450
J Am Coll Cardiol. 2018 Sep 11;72(11):1252-1263
pubmed: 30190003
J Am Diet Assoc. 1993 Jul;93(7):790-6
pubmed: 8320406
Acta Obstet Gynecol Scand. 2000 Jun;79(6):471-7
pubmed: 10857871
J Community Health. 2014 Feb;39(1):132-8
pubmed: 23959655

Auteurs

Ming Ding (M)

Department of Emergency Medicine, University of North Carolina, Chapel Hill.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Andre O Markon (AO)

Center for Food Safety and Applied Nutrition, Office of Analytics and Outreach, US Food and Drug Administration, College Park, Maryland.

Olivia E Jones-Dominic (OE)

Center for Food Safety and Applied Nutrition, Office of Analytics and Outreach, US Food and Drug Administration, College Park, Maryland.

Alexandra C Purdue-Smithe (AC)

Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Janet W Rich-Edwards (JW)

Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Beverly J Wolpert (BJ)

Center for Food Safety and Applied Nutrition, Office of Analytics and Outreach, US Food and Drug Administration, College Park, Maryland.

Jorge E Chavarro (JE)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH